Pitfalls in the diagnosis of primary amyloidosis

Cheng E. Chee, Martha Lacy, Ahmet Dogan, Steven R. Zeldenrust, Morie Gertz

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include immunomodulatory agents and high-dose chemotherapy with hematopoietic stem cell transplantation. However, other types of amyloidosis are increasingly recognized, such as familial amyloidosis and senile cardiac amyloidosis, and management of these conditions is different from that of AL amyloidosis. Congo red staining with exhibition of an apple-green birefringence is diagnostic of amyloid. Immunohistochemistry can detect amyloid deposits but has limitations, and newer molecular techniques such as mass spectrometry show promise in determining types of amyloidosis. Physicians need to be aware of clinical scenarios that can mimic AL amyloidosis to avoid misdiagnosis and harm to the patient.

Original languageEnglish (US)
Pages (from-to)177-180
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number3
DOIs
StatePublished - Jun 2010

Fingerprint

Amyloidosis
Familial Amyloidosis
Patient Harm
Birefringence
Congo Red
Hematopoietic Stem Cell Transplantation
Amyloid Plaques
Disease Management
Diagnostic Errors
Amyloid
Primary amyloidosis
Mass Spectrometry
Immunohistochemistry
Staining and Labeling
Physicians
Drug Therapy

Keywords

  • Fludarabine
  • Heavy chain
  • Light chain
  • Mass spectrometry
  • Senile amyloidosis
  • Transthyretin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Pitfalls in the diagnosis of primary amyloidosis. / Chee, Cheng E.; Lacy, Martha; Dogan, Ahmet; Zeldenrust, Steven R.; Gertz, Morie.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 3, 06.2010, p. 177-180.

Research output: Contribution to journalArticle

Chee, Cheng E. ; Lacy, Martha ; Dogan, Ahmet ; Zeldenrust, Steven R. ; Gertz, Morie. / Pitfalls in the diagnosis of primary amyloidosis. In: Clinical Lymphoma, Myeloma and Leukemia. 2010 ; Vol. 10, No. 3. pp. 177-180.
@article{e66b1e1edd0442bd8bf9eae0f6c66795,
title = "Pitfalls in the diagnosis of primary amyloidosis",
abstract = "Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include immunomodulatory agents and high-dose chemotherapy with hematopoietic stem cell transplantation. However, other types of amyloidosis are increasingly recognized, such as familial amyloidosis and senile cardiac amyloidosis, and management of these conditions is different from that of AL amyloidosis. Congo red staining with exhibition of an apple-green birefringence is diagnostic of amyloid. Immunohistochemistry can detect amyloid deposits but has limitations, and newer molecular techniques such as mass spectrometry show promise in determining types of amyloidosis. Physicians need to be aware of clinical scenarios that can mimic AL amyloidosis to avoid misdiagnosis and harm to the patient.",
keywords = "Fludarabine, Heavy chain, Light chain, Mass spectrometry, Senile amyloidosis, Transthyretin",
author = "Chee, {Cheng E.} and Martha Lacy and Ahmet Dogan and Zeldenrust, {Steven R.} and Morie Gertz",
year = "2010",
month = "6",
doi = "10.3816/CLML.2010.n.027",
language = "English (US)",
volume = "10",
pages = "177--180",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Pitfalls in the diagnosis of primary amyloidosis

AU - Chee, Cheng E.

AU - Lacy, Martha

AU - Dogan, Ahmet

AU - Zeldenrust, Steven R.

AU - Gertz, Morie

PY - 2010/6

Y1 - 2010/6

N2 - Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include immunomodulatory agents and high-dose chemotherapy with hematopoietic stem cell transplantation. However, other types of amyloidosis are increasingly recognized, such as familial amyloidosis and senile cardiac amyloidosis, and management of these conditions is different from that of AL amyloidosis. Congo red staining with exhibition of an apple-green birefringence is diagnostic of amyloid. Immunohistochemistry can detect amyloid deposits but has limitations, and newer molecular techniques such as mass spectrometry show promise in determining types of amyloidosis. Physicians need to be aware of clinical scenarios that can mimic AL amyloidosis to avoid misdiagnosis and harm to the patient.

AB - Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include immunomodulatory agents and high-dose chemotherapy with hematopoietic stem cell transplantation. However, other types of amyloidosis are increasingly recognized, such as familial amyloidosis and senile cardiac amyloidosis, and management of these conditions is different from that of AL amyloidosis. Congo red staining with exhibition of an apple-green birefringence is diagnostic of amyloid. Immunohistochemistry can detect amyloid deposits but has limitations, and newer molecular techniques such as mass spectrometry show promise in determining types of amyloidosis. Physicians need to be aware of clinical scenarios that can mimic AL amyloidosis to avoid misdiagnosis and harm to the patient.

KW - Fludarabine

KW - Heavy chain

KW - Light chain

KW - Mass spectrometry

KW - Senile amyloidosis

KW - Transthyretin

UR - http://www.scopus.com/inward/record.url?scp=77955878773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955878773&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.027

DO - 10.3816/CLML.2010.n.027

M3 - Article

C2 - 20511161

AN - SCOPUS:77955878773

VL - 10

SP - 177

EP - 180

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 3

ER -